135 related articles for article (PubMed ID: 38698618)
1. Stratification of Barrett's esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group.
Menon S; Norman R; Iyer PG; Ragunath K
Endoscopy; 2024 Jun; ():. PubMed ID: 38698618
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett's esophagus who have elevated genomic instability.
Das A; Callenberg KM; Styn MA; Jackson SA
Endosc Int Open; 2016 May; 4(5):E549-59. PubMed ID: 27227114
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
4. Improving cost-effectiveness of endoscopic surveillance for Barrett's esophagus by reducing low-value care: a review of economic evaluations.
Vissapragada R; Bulamu NB; Brumfitt C; Karnon J; Yazbeck R; Watson DI
Surg Endosc; 2021 Nov; 35(11):5905-5917. PubMed ID: 34312726
[TBL] [Abstract][Full Text] [Related]
5. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
6. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
Redston M; Noffsinger A; Kim A; Akarca FG; Rara M; Stapleton D; Nowden L; Lash R; Bass AJ; Stachler MD
Gastroenterology; 2022 Feb; 162(2):468-481. PubMed ID: 34757142
[TBL] [Abstract][Full Text] [Related]
7. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling.
Omidvari AH; Ali A; Hazelton WD; Kroep S; Lee M; Naber SK; Lauren BN; Ostvar S; Richmond E; Kong CY; Rubenstein JH; Lansdorp-Vogelaar I; Luebeck G; Hur C; Inadomi J
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):1961-1969. PubMed ID: 31816445
[TBL] [Abstract][Full Text] [Related]
9. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.
Omidvari AH; Hazelton WD; Lauren BN; Naber SK; Lee M; Ali A; Seguin C; Kong CY; Richmond E; Rubenstein JH; Luebeck GE; Inadomi JM; Hur C; Lansdorp-Vogelaar I
Gastroenterology; 2021 Aug; 161(2):487-494.e4. PubMed ID: 33974935
[TBL] [Abstract][Full Text] [Related]
10. A guide for surveillance of patients with Barrett's esophagus.
Provenzale D; Kemp JA; Arora S; Wong JB
Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
12. Surveillance in Barrett's esophagus: a failed premise.
Inadomi JM
Keio J Med; 2009 Mar; 58(1):12-8. PubMed ID: 19398879
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom.
Pollit V; Graham D; Leonard C; Filby A; McMaster J; Mealing SJ; Lovat LB; Haidry RJ
Curr Med Res Opin; 2019 May; 35(5):805-815. PubMed ID: 30479169
[TBL] [Abstract][Full Text] [Related]
14. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic surveillance in Barrett's esophagus.
Lunedei V; Bazzoli F; Pozzato P; De Luca L; Zagari RM; Fossi S; Ricciardiello L; Maltoni S; Roda E
Minerva Gastroenterol Dietol; 2002 Jun; 48(2):63-71. PubMed ID: 16489297
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
[TBL] [Abstract][Full Text] [Related]
17. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
18. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
